2月17日，诺和诺德发布公告称，欧盟委员会已批准Wegovy （司美格鲁肽注射液）新的7.2 mg每周一次 维持剂量，用于成人肥胖症患者。 Wegovy 7.2 mg已在英国获批并上市，同时，美国食品药品监督管理局（FDA）及其他多个国家的注册 机构正在对其注册申请进行审批。 此次批准意味着，欧盟医生现可以开具7.2 mg剂量的处方，即一次性注射三针2.4 mg，仍为每周注射一 次。诺和诺德已向欧盟递交7.2 mg单剂量注射笔的上市许可申请，如获批准有望于今年上市。这也意味 着，在欧盟，成人肥胖症患者在使用Wegovy 2.4 mg（至少4周）后，如需实现更大幅度的减重并同时保 持肌肉功能，可直接提升至7.2 mg剂量。 ...

21世纪经济报道记者韩利明 2月27日消息显示，欧盟委员会已批准Wegovy®（司美格鲁肽注射液）新的7.2 mg每周一次维持剂量， 用于成人肥胖症患者。这一批准为医生提供了新的治疗选择，以帮助使用2.4 mg剂量后仍需更多减重的 成人患者。此项批准决定基于欧洲药品管理局人用药品委员会（CHMP）于2025年12月12日发布的积极 审评意见。 此次批准意味着，欧盟医生现可以开具7.2 mg剂量的处方，即一次性注射三针2.4 mg，仍为每周注射一 次。诺和诺德已向欧盟递交7.2 mg单剂量注射笔的上市许可申请，如获批准有望于今年上市。这也意味 着，在欧盟，成人肥胖症患者在使用Wegovy® 2.4 mg（至少4周）后，如需实现更大幅度的减重并同时 保持肌肉功能，可直接提升至7.2 mg剂量。 Wegovy® 7.2 mg已在英国获批并上市，同时，美国食品药品监督管理局（FDA）及其他多个国家的注 册机构正在对其注册申请进行审批。 诺和诺德国际运营部执行副总裁林意明（EmilKongshjLarsen）表示："此次获批是帮助肥胖人群实现更 为显著减重的又一重要进展。这一新剂量为医疗专业人士提供了更大的灵活性，使其 ...

Financial Performance - The company reiterated its revenue guidance for 2026, expecting total revenue between $59.5 billion and $62.5 billion, with approximately $5 billion from COVID-related products and an impact of about $1.5 billion from patent expirations. Adjusted earnings per share guidance is set at $2.80 to $3.00 [2] Product Development Progress - The company plans to initiate around 20 key clinical trials in 2026, with 10 focused on obesity assets, including the further development of the long-acting GLP-1 receptor agonist PF-3944 (MET-097i), which has shown significant weight loss effects in its phase 2b study [3] - In oncology, Padcev (enfortumab vedotin) in combination with pembrolizumab received FDA approval in November 2025 for perioperative treatment of bladder cancer, while Tukysa and Braftovi have shown positive efficacy in breast and colorectal cancer trials [3] Strategic Initiatives - In November 2025, the company completed the acquisition of Metsera for approximately $7 billion, aimed at strengthening its pipeline in obesity and metabolic diseases, marking its entry into this high-growth area [4] - The company continues to expand its pipeline through collaborations, such as the agreement with YaoPharma for small molecule GLP-1 receptor agonists, although this is still in the early stages [4] Operational Efficiency - The adjusted sales cost ratio decreased to 24.2% in 2025, with sales and administrative expenses declining by 7% year-over-year, reflecting the company's ongoing efforts to enhance operational efficiency through digitalization and resource optimization [5]

Financial Performance - In Q4 2025, the company reported revenue of $17.56 billion, with a 9% year-over-year growth in non-COVID business [1] - Total revenue for the year 2025 was $62.6 billion, with a 6% growth in core non-COVID business [1] - The company reaffirmed its revenue guidance for 2026, projecting between $59.5 billion and $62.5 billion, including approximately $5 billion from COVID-related products and accounting for about $1.5 billion impact from patent expirations [1] - Adjusted earnings per share guidance for 2026 is set between $2.80 and $3.00 [1] Product Development Progress - In 2026, the company plans to initiate around 20 key clinical trials, with 10 focused on obesity assets [2] - The Phase 2b study of the ultra-long-acting GLP-1 receptor agonist PF-3944 (MET-097i) has achieved its primary endpoint [2] - The oncology sector has seen several regulatory breakthroughs, including FDA approval in November 2025 for Padcev in combination with pembrolizumab for perioperative treatment of bladder cancer [2] - Tukysa and Braftovi have shown significant efficacy in trials for breast and colorectal cancers [2] Strategic Initiatives - In November 2025, the company completed the acquisition of Metsera, with a total transaction value of approximately $7 billion, aimed at strengthening its pipeline in obesity and metabolic diseases [3] - The company has improved operational efficiency through cost control, with the adjusted sales cost ratio decreasing to 24.2% in 2025, and sales and administrative expenses declining by 7% year-over-year [3]

Core Insights - Alveus Therapeutics has completed a $159.8 million financing round aimed at developing obesity treatment solutions, focusing on maintaining long-term weight loss for patients [1][4] - The company highlights significant shortcomings in current obesity medications, with approximately 50% of patients discontinuing treatment within a year and 85% by the end of the second year [1][4] - Alveus is developing a drug named ALV-100, which combines GLP-1 receptor activation with GIP receptor blockade, aiming for long-lasting weight loss with lower dosing frequency compared to existing therapies [1][4] Company Development - The CEO of Alveus, Raj Kannan, stated that the focus of the weight loss market is shifting from merely achieving weight loss to maintaining weight loss quality, enhancing drug tolerability, and optimizing body composition [2][5] - In addition to ALV-100, Alveus is advancing another candidate drug, ALV-200, which is a selective therapy based on amylin, currently in the regulatory submission phase, designed to help patients retain lean muscle mass during weight loss [6] - The company aims to maintain operational independence while considering strategic partnerships as drug development progresses into later stages [6] Market Context - Predictions indicate that by 2030, the obesity rate in the U.S. could reach 50%, with obesity linked to over 200 health complications [2][6] - According to the National Institutes of Health, the obesity rate among U.S. adults is projected to exceed 40% by 2024 [3][6]

Core Insights - Novo Nordisk's semaglutide injection (brand name: Ozempic) has received approval from the National Medical Products Administration (NMPA) in China for cardiovascular indications, aimed at reducing the risk of major cardiovascular adverse events in adults with cardiovascular disease and a BMI ≥ 27 kg/m² [1][2] Group 1: Product Approval and Efficacy - The approval is based on the SELECT trial, which is the largest cardiovascular outcomes trial completed for patients with obesity and cardiovascular disease, involving 17,604 participants [4] - The SELECT trial results indicated that semaglutide injection reduced the risk of major adverse cardiovascular events (MACE) by 20%, cardiovascular death by 15%, heart failure composite endpoint by 18%, and all-cause mortality by 19% compared to placebo [4] - Early treatment with semaglutide showed protective effects on the heart before significant weight loss occurred, suggesting benefits in reducing MACE risk regardless of weight reduction [4] Group 2: Market Context and Health Implications - Approximately 4 million people die from cardiovascular diseases in China each year, accounting for over 40% of total deaths, with obesity being a significant independent risk factor for cardiovascular morbidity and mortality [3] - The treatment guidelines in both Europe and China emphasize the importance of weight management in overweight/obese patients to lower cardiovascular risks, with semaglutide being the only drug recommended for this purpose [3][4] - Real-world studies, such as the STEER study, demonstrated that patients treated with semaglutide had a 57% lower risk of heart attack, stroke, and all-cause mortality compared to those treated with tirzepatide, reinforcing the unique cardiovascular benefits of semaglutide [5] Group 3: Company Strategy and Future Outlook - Novo Nordisk aims to transform obesity treatment concepts and improve cardiovascular outcomes for overweight and obese patients through the broader clinical application of semaglutide [5] - The company is committed to addressing diverse needs in obesity treatment and continues to innovate in its research pipeline to combat obesity stigma and promote effective prevention strategies [5]

Group 1 - The company, Lai Kai Pharmaceutical-B (02105), has initiated the enrollment of subjects for a Phase I multi-dose expansion study of LAE102 for the treatment of obesity in China [1] - The Phase I study is a randomized, double-blind, placebo-controlled trial aimed at evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of LAE102 (subcutaneous injection) in 60 overweight/obese subjects [1] - Subjects will be randomly assigned to either the LAE102 group or the placebo group, receiving treatment for a duration of 6 months [1] Group 2 - The multi-dose expansion study is designed to further assess the efficacy and safety characteristics of LAE102 after longer-term treatment, building on positive one-month treatment results observed in a previous MAD study [1] - The company is committed to providing this precision treatment for patients with obesity or metabolic diseases who require new therapeutic options [1]

Core Viewpoint - The article discusses the urgent need for new mechanisms in obesity treatment, highlighting the development of a novel siRNA candidate drug, SGB-7342, by Shengyin Biotech, which targets INHBE for obesity treatment [4][11]. Group 1: Obesity as a Public Health Challenge - Obesity is a chronic metabolic disease characterized by abnormal or excessive fat accumulation, significantly increasing the risk of cardiovascular diseases, type 2 diabetes, and various cancers [5]. - The global population of obese individuals has surpassed 1 billion and is expected to reach approximately 1.37 billion by 2035; in China, there are about 180 million adult obesity patients [6]. Group 2: Current Treatment Limitations - Current mainstream obesity treatments primarily involve GLP-1 receptor agonists, which suppress appetite through the central nervous system but have drawbacks such as gastrointestinal side effects, muscle loss risk, and weight regain after discontinuation [7]. Group 3: RNAi Therapy as a New Approach - RNAi therapy offers a differentiated treatment strategy that does not rely on central appetite regulation, aiming to regulate fat metabolism at the source by targeting key genes involved in fat breakdown and storage [8]. - This approach is expected to selectively reduce fat while preserving muscle mass and improving overall metabolic health, potentially lowering the risk of adverse effects associated with traditional therapies [8]. Group 4: INHBE as a Novel Metabolic Target - The INHBE gene, primarily expressed in the liver, encodes the secreted protein Activin E, which regulates fat breakdown and energy storage by binding to the ALK7 receptor in adipose tissue [9]. - Genetic studies indicate that individuals with INHBE loss-of-function mutations exhibit favorable metabolic traits, providing a biological basis for targeting INHBE in drug development [9]. Group 5: SGB-7342 Candidate Drug - SGB-7342 is a siRNA candidate drug targeting INHBE for obesity treatment, utilizing Shengyin Biotech's proprietary GalNAc conjugation delivery technology for precise liver targeting [10]. - The mechanism involves silencing INHBE mRNA in the liver to lower Activin E protein levels, promoting fat breakdown without inducing muscle loss, thereby improving metabolic disorders and insulin resistance [10]. - Preclinical studies show that SGB-7342 leads to significant weight loss and improved body composition while maintaining muscle mass, demonstrating good safety and tolerability [10]. Group 6: Future Outlook - Obesity is recognized as a complex systemic metabolic disease rather than merely a weight issue, with significant unmet clinical needs in the global obesity treatment landscape [11]. - RNAi therapy, with its novel mechanism directly targeting metabolic pathways, is expected to offer differentiated advantages in selective fat reduction, muscle protection, and long-lasting treatment [11].

Core Insights - Eli Lilly's new obesity treatment, retatrutide, has shown promising results in clinical trials, helping patients lose over 23% of their body weight, potentially making it the most effective weight loss therapy to date [1] - The trial also demonstrated significant improvement in knee osteoarthritis pain symptoms, with over 62% of participants reporting relief [1] - The results exceeded Wall Street's expectations, leading to a nearly 4% increase in Eli Lilly's stock price [1] Clinical Trial Data - The trial lasted 68 weeks and included patients with obesity and knee osteoarthritis, a condition closely linked to obesity [2] - Two dosage groups (9 mg and 12 mg) were tested, both effectively reducing cardiovascular risk markers and blood pressure, with some patients experiencing complete relief from knee pain [2] - Approximately 18% of patients in the highest dosage group experienced adverse reactions, with common symptoms including nausea, diarrhea, and constipation [2] Patient Insights - Patients with a Body Mass Index (BMI) below 35 were more likely to withdraw from the trial, with some stopping due to excessive weight loss [3] - Eli Lilly's Chief Scientific Officer indicated that retatrutide is more suitable for patients with significantly high BMI or those needing substantial weight loss to improve obesity-related complications [3]

Core Viewpoint - Fosun Pharma has signed a licensing agreement with Pfizer for the development and commercialization of the oral small molecule GLP-1 receptor agonist YP05002, which is aimed at treating type 2 diabetes and obesity-related diseases [1][2]. Group 1 - The licensing agreement grants Pfizer exclusive rights to develop, use, produce, and commercialize YP05002 globally across all therapeutic areas for humans and animals [1]. - Fosun Pharma's subsidiary, YaoYao Pharmaceutical, will receive an upfront payment of $150 million and up to $350 million in milestone payments based on clinical and commercialization progress [1]. - Additionally, Fosun Pharma could earn up to $1.585 billion in sales milestone payments based on the annual net sales performance of the licensed product [1]. Group 2 - YP05002 is developed in-house by the company and is designed to activate the GLP-1 receptor, promoting insulin secretion and reducing glucagon secretion, while also suppressing gastric emptying and appetite [2]. - The potential indications for YP05002 include long-term weight management, type 2 diabetes, and metabolic dysfunction-related fatty liver disease (non-alcoholic steatohepatitis) [2].